{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '105', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.10', 'Medical Resource Utilization and Health Economics', 'All-cause hospitalizations and emergency room visits must be reported in the eCRF, from the', 'time of treatment randomization through 90 days after cessation of study intervention, or', '30 days after cessation of study intervention, if the participant initiates new anticancer', 'therapy, whichever is earlier.', '8.11', 'Visit Requirements', 'NOTE: As of Amendment 007-06, the Second-course Treatment Phase has been', 'removed from the study. The following subsections have been updated accordingly.', 'Visit requirements are outlined in the SoA (Section 1.3). Specific procedure-related details', 'are provided in Section 8.', 'Unscheduled visits are permitted at any time during the course of the study.', '8.11.1', 'Screening', 'Documented informed consent must be provided before performing any protocol-specific', 'procedure. Results of a test performed before the participant signs the ICF as part of routine', 'clinical management are acceptable in lieu of a screening test if performed within the', 'specified time frame. Screening procedures are to be completed within 28 days before the', 'first dose of study intervention except for the following:', 'Laboratory tests are to be performed per the SoA (Section 1.3).', 'Evaluation of ECOG is to be performed at screening, within 7 days before Cycle 1', 'but before randomization.', 'For WOCBP, a urine or serum pregnancy test will be performed within 24 hours', 'before the first dose of study intervention. If urine pregnancy results cannot be', 'confirmed as negative, a serum pregnancy test will be required (performed by the', 'local study site laboratory).', 'Participants may be rescreened after initially failing to meet the inclusion/exclusion criteria.', 'Results from assessments during the initial screening period are acceptable in lieu of a repeat', 'screening test if performed within the specified time frame and the corresponding', 'inclusion/exclusion criteria are met. Participants who are rescreened will retain their original', 'screening number.', '8.11.2', 'Initial Treatment Phase', 'Visit requirements are outlined in the SoA (Section 1.3). Specific procedure-related details', 'are provided in Section 8.1.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '106', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.11.3', 'Second-course Treatment Phase', 'NOTE: As of Amendment 007-06, the Second-course Treatment Phase has been', 'removed from the study.', '8.11.4', 'Discontinued Participants Continuing to be Monitored in the Study', 'The Discontinuation Visit should occur at the time study intervention is discontinued for any', 'reason. If the Discontinuation Visit occurs 30 days from the last dose of study intervention, at', 'the time of the mandatory Safety Follow-up Visit, the Discontinuation Visit procedures and', 'any additional safety follow-up procedures should be performed.', 'Visit requirements are outlined in the SoA. Additional details regarding participant', 'withdrawal and discontinuation are presented in Section 8.1.9.', '8.11.5', 'Poststudy', '8.11.5.1', 'Safety Follow-up Visit', 'The mandatory Safety Follow-up Visits should be conducted approximately 30 days after the', 'last dose of study intervention or before the initiation of a new anticancer treatment,', 'whichever comes first.', '8.11.5.2', 'Efficacy Follow-up Visits', 'NOTE: After amendment 007-06, imaging obtained on study will be submitted to the', 'imaging vendor but these will not be assessed, verification of PD is no longer needed', 'before treatment discontinuation, and posttreatment imaging is no longer required.', 'Participants who complete the protocol-required cycles of study intervention or who', 'discontinue study intervention for a reason other than PD will move into Efficacy Follow-up', 'Phase and should be assessed as outlined in the SoA (Section 1.3) to monitor disease status.', 'Every effort should be made to collect information regarding disease status until the start of', 'new anticancer therapy, PD, death, or end of study. Information regarding poststudy', 'anticancer treatment will be collected if new treatment is initiated. Participants who', 'completed all efficacy assessments and/or will not have further efficacy assessments must', 'enter Survival Follow-up Phase.', '8.11.5.3', 'Survival Follow-up Assessments', 'Participants who experience confirmed PD or start a new anticancer therapy will move into', 'the Survival Follow-Up Phase and should be contacted by telephone approximately every', '12 weeks (or more often as required) to assess survival status until death, withdrawal of', 'consent, or the end of the study, whichever occurs first. Participants may be contacted for', 'survival status at any time during the course of the study.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}